3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
26
Nivolumab
18
enfortumab vedotin
7
avelumab
6
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
fludarabine
4
cabozantinib
4
Gemcitabine
4
Cyclophosphamide
4
Carboplatin
4
Specimen Handling
3
Interleukin-2
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
aldesleukin
2
Platinum
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
vinflunine
1
veliparib
1
valrubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Transitional Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled